Best in Biotech 3 Oct 2024 Six biotechs driving progress in Duchenne muscular dystrophy …dystrophin protein. The trial results showed that the candidate had a 5.5% mean absolute unadjusted dystrophin in patients after 24 weeks. Wave also reported mean absolute muscle content-adjusted dystrophin expression… October 3, 2024 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2025 AstraZeneca bets on Asia: a surge of deals in March amid fraud probe …BioMed to gain an option to license multiple programs derived from the latter’s Harbour Mice fully human antibody technology platform. The platform creates heavy chain antibodies – around half the… March 31, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 FDA boosts Antengene pancreatic cancer treatment Biopharma company Antengene Corporation Limited says ATG-101, the company’s in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an orphan drug designation (ODD) by the U.S. Food and Drug Administration… September 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2023 von Willebrand disease treatment gets FDA orphan drug designation The U.S. Food and Drug Administration (FDA) has granted Vega Therapeutics, Inc. orphan drug designation for its antibody therapy, VGA039, for the treatment of the rare bleeding disorder, von Willebrand… June 2, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Jun 2023 Acepodia raises $100M financing to boost cell therapies Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its antibody-cell conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, has announced… June 8, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2017 Janssen’s Psoriasis Drug is Given a Thumbs Up for Use in Europe …3-10% or more than 10% of the body is affected. Guselkumab (Tremfya) is a human anti-IL-23 monoclonal antibody developed by Janssen and generated using MorphoSys’s Human Combinatorial Antibody Library (HuCAL)… November 23, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 8 Sep 2022 Integral Molecular joins FDA’s ISTAND program …by allowing them to be used in regulatory (IND, NDA or BLA) applications without needing the FDA to reconsider and reconfirm their suitability. Integral Molecular said antibodies and antibody-based therapies,… September 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jun 2023 Astellas developing new gastric cancer drug …antibody, for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive. If approved, zolbetuximab would be the first… June 9, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 8 Oct 2024 Top biotech deals of September 2024 …of Clairvoyant’s phase 2 psilocybin candidate being tested for alcohol use disorder. And finally, U.S.-based cancer company OncoC4 joined forces with AcroImmune to add an Investigational New Drug Application (IND)-ready… October 8, 2024 - 6 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jun 2025 Top biotech deals in May 2025 …the hands of Sanofi. Now, it will compete with fellow pharma giant Novartis advancing its TREM2-targeting candidate in the Alzheimer’s treatment space. Meanwhile, California-based biotech BioMarin Pharmaceutical has bought Massachusetts-based… June 2, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022 Alchemab Therapeutics receives £1.7M grant to work on therapy for Huntington’s disease …to accelerate development of our antibody and deliver some hope for patients.” This is the second grant awarded to Alchemab and MDC. The financing will support preclinical development of the… December 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 17 Oct 2022 Clinical trial of treatment for advanced solid tumors approved …about a phase 1b/2 clinical trial of its in-house developed Ivonescimab (PD-1/VEGF bi-specific AK112) combined with Drebuxelimab (CD73, AK119). AK112 is the first PD-1/VEGF bi-specific antibody that entered phase 3… October 17, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email